Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Immuneering Corp (NASDAQ:IMRX) Chief People Officer Leah R. Neufeld reported purchasing 700 shares of Class A Common Stock on July 2, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at a price of $3.5695, totaling $2498. The insider purchase comes as the stock has shown remarkable strength, delivering a 216% return over the past year. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt.
Following the transaction, Neufeld directly owns 10729 shares of Immuneering Corp. With analyst price targets ranging from $3.50 to $21.00 and current trading levels suggesting slight undervaluation based on InvestingPro’s Fair Value analysis, the stock continues to draw attention from both insiders and analysts alike.
In other recent news, Immuneering Corporation announced promising results from its Phase 2a clinical trial for its lead drug, atebimetinib, in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer. The trial reported a 94% overall survival rate and a 72% progression-free survival rate at six months, surpassing standard care benchmarks. Mizuho (NYSE:MFG) responded to these results by raising its price target for Immuneering to $10 from $8 and maintained an Outperform rating, citing the drug’s favorable safety profile. The positive trial results have led Immuneering to increase the trial’s target enrollment and plan a pivotal trial in 2026. Additionally, the company held its Annual Meeting of Stockholders, where three Class I directors were elected, and the appointment of RSM US LLP as the independent registered public accounting firm was ratified. These developments highlight Immuneering’s ongoing efforts in advancing cancer treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.